Skip to Content

Join the 'Mircera' group to help and get support from people like you.

Mircera News

Anemia Drugs May Not Boost Kidney Patients' Well-Being: Study

Posted 16 Feb 2016 by Drugs.com

MONDAY, Feb. 15, 2016 – The pricey anemia drugs often given to people with chronic kidney disease may make no difference in how they feel day to day, a new research review confirms. Researchers said the study results back up current guidelines on how to use the drugs, called erythropoietin-stimulating agents (ESAs). These include the injection drugs marketed under the names Procrit, Epogen and Aranesp. Patients may still benefit from the medications because they reduce the need for blood transfusions to treat severe anemia, said Dr. Navdeep Tangri, senior researcher on the study. "But this should close the book on the idea that these drugs help with exhaustion and improve patients' quality of life," said Tangri, an attending doctor at Seven Oaks General Hospital Renal Program in Manitoba, Canada. However, one expert argued that while on average, that is true, some patients do feel ... Read more

Related support groups: Anemia, Renal Failure, Chronic Kidney Disease, Aranesp, Peritoneal dialysis, Procrit, Epogen, Renal Osteodystrophy, Darbepoetin Alfa, Mircera, Anemia Associated with Chronic Disease, Epoetin Beta-Methoxy Polyethylene Glycol, Omontys, Peginesatide, Hyperphosphatemia of Renal Failure, Epoetin Alfa

Use Anemia Drugs for Cancer Patients With Caution, Experts Say

Posted 26 Oct 2010 by Drugs.com

TUESDAY, Oct. 26 – Physicians need to use caution when giving a class of drugs called erythropoiesis-stimulating agents (ESAs) to cancer patients who have anemia caused by chemotherapy, according to new medical guidelines. And with rare exceptions, ESAs should not be given to cancer patients who are not receiving chemotherapy, according to joint guidelines issued by the American Society of Hematology and the American Society of Clinical Oncology. ESAs (marketed as Procrit, Epogen and Aranesp) stimulate the bone marrow to produce more red blood cells but are associated with shorter survival and increased risk of blood clots and tumor progression, the guidelines noted. However, ESAs reduce the need for red blood cell transfusions, which carry a risk of serious infection and adverse reactions in the immune system. The guidelines offer specific recommendations on the use of ESAs. Among ... Read more

Related support groups: Aranesp, Procrit, Epogen, Darbepoetin Alfa, Mircera, Epoetin Beta-Methoxy Polyethylene Glycol, Epoetin Alfa, Anemia - Chemotherapy Induced

Anemia Drugs Hold Dangers for Kidney Patients

Posted 5 May 2010 by Drugs.com

WEDNESDAY, May 5 – The powerful drugs used to fight anemia caused by kidney failure increase the risk for cardiovascular problems such as heart attack, a major study has found. A meta-analysis of 27 trials, which included more than 10,000 people who were given the drugs, known as erythropoiesis-stimulating agents (ESAs), found that those who took the drugs at the highest dosages had a 51 percent increased risk for stroke and a 33 percent increased risk for thrombosis, or blockage of an artery. The study, by an international group of experts, was published online May 3 in Annals of Internal Medicine. The increased risk for death (9 percent) and serious cardiovascular events such as heart attacks (15 percent) did not reach statistical significance, the analysis found. The U.S. Food and Drug Administration has acted to control the use of ESAs marketed as Epogen, Procrit and Aranesp, which ... Read more

Related support groups: Aranesp, Procrit, Epogen, Mircera, Darbepoetin Alfa, Epoetin Beta-Methoxy Polyethylene Glycol, Epoetin Alfa

For Some on Dialysis, Anemia Drugs Pose Risks

Posted 2 Mar 2010 by Drugs.com

TUESDAY, March 2 – Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown. People on dialysis with severe anemia, according to the study, tend to live longer when given high doses of the drugs – known as erythropoiesis-stimulating agents (ESAs) and marketed as Epogen, Procrit and Aranesp. But it found that the drugs increase the risk for dying prematurely among people with mild anemia. ESAs, which increase the production of red blood cells, are approved by the U.S. Food and Drug Administration to treat the anemia caused by cancer chemotherapy and AIDS drugs as well as kidney failure. But safety concerns have limited their use, especially among cancer patients. Over the next few months, the FDA and the U.S. Centers for Medicare and Medicaid Services plan to review the use of ESAs in the treatment ... Read more

Related support groups: Aranesp, Procrit, Epogen, Anemia Associated with Chronic Renal Failure, Darbepoetin Alfa, Mircera, Epoetin Beta-Methoxy Polyethylene Glycol, Epoetin Alfa

Ask a Question

Further Information

Related Condition Support Groups

Anemia Associated with Chronic Renal Failure

Mircera Patient Information at Drugs.com